Today's Date: May 8, 2021
Sen. Jon Ossoff Announces that Clark Atlanta University Will Receive Approximately $16.4 Million from the American Rescue Plan   •   Supporting Local Communities: PG&E Contributes $200,000 to Celebrate and Support the Asian American Pacific Islander Communi   •   Waldencast Acquisition Corp. Announces the Separate Trading of Its Class A Ordinary Shares and Redeemable Warrants Commencing Ma   •   HeyMama, in partnership with Lincoln, Launch the First Ever Motherhood on the Resume Campaign   •   Graymoor Ecumenical and Interreligious Institute Shares Theme for 2022 Week of Prayer for Christian Unity   •   Toyota Ranks 7th on DiversityInc's Top 50 Companies for Diversity   •   Skypod Supports American Pregnancy Association   •   MedShare to Give Expectant Mothers in Underserved Bay Area Communities Access to State-of-the-Art Philips Ultrasound Imaging Sol   •   Hello Sunshine’s Fair Play Brand, Glamour and CVS To Host “Dare to Self-Care” Virtual Wellness Event on May 10   •   The Tech Convenes Top STEM Professionals to Advise Young Women on Career Paths   •   IPG Mediabrands Shares Media Equity Commitment to Encourage Investment in Black-Owned Media   •   Publix Accepts Walk-in Customers for COVID‑19 Vaccinations in All Seven of Its States   •   Short documentary Dear Georgina spotlighting life of Passamaquoddy elder streaming launch May 7   •   Women in Manufacturing Association Announces “Moms in MFG,” a New Event for Moms Working in the Manufacturing Sector   •   Minister Miller talks about mental wellness during the pandemic   •   AHF Issues $100M Homeless Challenge to Mayor Garcetti, L.A. City Council in New L.A. Times Ad   •   HCSS Hosts TWU Houston 2021 Graduation With Drive-Through Event   •   United Way of King County Launches New Campaign to Address Growing Food Insecurity Due to Pandemic   •   UBS Declares Coupon Payments on 5 ETRACS Exchange Traded Notes   •   Six Flags Hurricane Harbor to Reopen May 15
Bookmark and Share

Solace Therapeutics Announces that Dr. Cindy Basinski and Team at CMB Research Enrolls First Patient in US Pivotal Clinical Tria

NEWBURGH, Ind. , April 21 /Businesswire/ - Dr. Cindy Basinski and Team at CMB Research, has enrolled their first patient in the VESAIR Clinical Trial. The VESAIR Clinical Trial is being conducted in several distinguished clinics throughout the US to test the safety and efficacy of the Vesair Bladder Control Balloon procedure.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210421005543/en/

(Graphic: Business Wire)

(Graphic: Business Wire)

“I am delighted to be participating in the VESAIR Clinical Study. SUI is not life-threatening, but if left untreated, it can greatly diminish a woman’s Quality of Life. Having a non-surgical option would be a great alternative for the nearly 1 in 2 women over the age of 50, who suffer from this condition,” said Cindy Basinski, MD, Principal Investigator for the VESAIR Clinical Study.

About Stress Urinary Incontinence and the Vesair Bladder Control System

Women with Stress Urinary Incontinence (SUI) typically experience sudden increases in bladder pressure during physical movement, for example coughing, laughing, sneezing, or during exercise. When this increased bladder pressure exceeds the ability of the urethral sphincter to withstand pressure, leakage occurs. Unlike currently available SUI treatments that focus on improving the urethral closure force, the Vesair Bladder Control System is designed to reduce rapid increases in bladder pressure through the placement of a compressible air-filled balloon in the bladder. The balloon acts like a “shock-absorber” to slow rapid changes in pressure and reduce leakage. The uninflated balloon is placed into the bladder through the urethra and subsequently inflated. Balloon placement is performed during an in-office procedure that does not require anesthesia. When necessary, the balloon is deflated and removed in a similar in-office procedure. Most women manage their SUI with absorbent pads and are reluctant to undergo surgery for a variety of reasons. To learn more about the VESAIR Clinical Trial visit; www.vesairstudy.com.

About Solace Therapeutics, Inc.

Solace Therapeutics is an emerging women’s health company focused on a new office-based treatment for symptoms of female SUI. SUI is the most prevalent form of incontinence among women and affects an estimated 15 million adult women in the U.S. These women choose to manage their SUI by utilizing absorbent products such as protective pads versus seeking medical help. Solace is dedicated to improving the quality of life for women whose daily life is disrupted by their incontinence. Please visit www.solacetx.com to learn more about the company and review results from the first two clinical trials.


STORY TAGS: Photo/Multimedia, General Health, Women, Consumer, Health, Clinical Trials, United States, North America, Indiana, Product/Service,

Video

White House Live Stream
LIVE VIDEO EVERY SATURDAY
Breaking News
alsharpton Rev. Al Sharpton
9 to 11 am EST
jjackson Rev. Jesse Jackson
10 to noon CST


Video

LIVE BROADCASTS
Sounds Make the News ®
WAOK-Urban
Atlanta - WAOK-Urban
KPFA-Progressive
Berkley / San Francisco - KPFA-Progressive
WVON-Urban
Chicago - WVON-Urban
KJLH - Urban
Los Angeles - KJLH - Urban
WKDM-Mandarin Chinese
New York - WKDM-Mandarin Chinese
WADO-Spanish
New York - WADO-Spanish
WBAI - Progressive
New York - WBAI - Progressive
WOL-Urban
Washington - WOL-Urban

Listen to United Natiosns News